The Form Bio team, from L-R: co-CEO Andrew Busey; director of bioinformatics Brandi Cantarel; co-CEO Kent Wakeford; chief strategy officer Claire Aldridge; plus Colossal CEO Ben Lamm (Business Wire)
September 27, 2022 11:05 AM EDTUpdated 12:21 PM
Financing
Startups

George Church’s wool­ly mam­moth re­vival biotech Colos­sal spins out com­pu­ta­tion­al bio out­fit

Lei Lei Wu

News Reporter

Colos­sal Bio­sciences has a some­what lofty goal — re­vive the wool­ly mam­moth. When the biotech launched in 2021, its CEO Ben Lamm com­pared its mis­sion to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

A service from the Financial Times